Skip to main content

Peer Review reports

From: Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland

Original Submission
14 Jan 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
11 Mar 2022 Reviewed Reviewer Report - Peter Quon
16 Mar 2022 Reviewed Reviewer Report
11 Apr 2022 Author responded Author comments - Arjun Bhadhuri
Resubmission - Version 3
11 Apr 2022 Submitted Manuscript version 3
29 Apr 2022 Reviewed Reviewer Report
9 May 2022 Reviewed Reviewer Report - Peter Quon
8 Jun 2022 Author responded Author comments - Arjun Bhadhuri
Resubmission - Version 4
8 Jun 2022 Submitted Manuscript version 4
Publishing
17 Jun 2022 Editorially accepted
28 Jun 2022 Article published 10.1186/s12913-022-08211-y

You can find further information about peer review here.

Back to article page